MRNA
MRNA
Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
2
$6.01M
Insider Sales
24
$98.75M
Total Volume
$104.75M
47 transactions
Net Activity
$92.74M
Net selling
Sentiment Rating
Moderate AccumulationCEO Conviction Index
High Conviction Accumulation
Key Drivers
- •Heavy distribution: sales represent 94% of total transaction value.
- •Minor cluster buying: 2 unique insiders purchased shares.
- •CEO buying activity detected. When chief executives put their own money at risk, it is historically a strong bullish signal.
- •High accumulation: total purchase value exceeds $1M.
- •Significant liquidation: total sale value exceeds $10M.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
Multiple Insiders
S - Sale+OE Insiders
$3409.79B total
Hoge Stephen
Pres
$62.39M total
Bancel Stephane
CEO
$33.72M total
Mock James M
CFO
$4.75M total
Klinger Shannon Thyme
GC
$1.47M total
Quick Actions
MRNA has an insider buy conviction of 6%, compared to the Unknown sector buy average of 6%. MRNA ranks #106 in insider activity out of 569 tracked companies in its industry.
Over the last 90 days, corporate insiders at MRNA (MRNA) engaged in a total of 47 transactions reported via SEC Form 4 filings. Among these, 2 were open-market purchases and 24 were sales. The total volume of insider trading reached $104.75M.
The net insider activity for MRNA shows a net selling bias of $92.74M. This activity represents a 6% buy ratio, suggesting that insiders are currently bearish on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Sale by Multiple Insiders (P - Purchase Insiders), who traded 21.27M shares valued at $3409.79B on Mar 3, 2025.
mRNA-1283 Associated With Lower Risk of Medically Attended COVID-19 Than BNT162b2 in Older Veterans
What A Cancer Vaccine Stumble Means For Moderna Stock
MRNA Stock Gains Over $4B in a Week: Time to Buy, Hold or Sell?
Moderna drops marking longest losing streak since 2024
Moderna Shares Are Up 350% in 2026. Is the Stock a Buy Now?
Moderna (NASDAQ:MRNA) Stock Price Up 4.9% - Here's Why
FAQs About MRNA Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for MRNA.